<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1004257221
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Erleada
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        APALUTAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        240
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        10522.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="JANSSEN PHARMACEUTICA N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            JANSSEN PHARMACEUTICA N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Janssen-Cilag International NV 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Erleada is</strong></p><p>Erleada is a cancer medicine that contains the active substance &lsquo;apalutamide&rsquo;.</p><p>&nbsp;</p><p><strong>What Erleada is used for</strong></p><p>It is used to treat adult men with prostate cancer that:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has metastasised to other parts of the body and still responds to medical or surgical treatments that lower testosterone (also called hormone-sensitive prostate cancer).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has not metastasised to other parts of the body and no longer responds to medical or surgical treatment that lowers testosterone (also called castration-resistant prostate cancer).</p><p>&nbsp;</p><p><strong>How Erleada works</strong></p><p>Erleada works by blocking the activity of hormones called androgens (such as testosterone). Androgens can cause the cancer to grow. By blocking the effect of androgens, apalutamide stops prostate cancer cells from growing and dividing.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Erleada </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to apalutamide or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are a woman who is pregnant or may become pregnant (see the Pregnancy and contraception section below for more information).</p><p>&nbsp;</p><p>Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking this medicine if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had fits or seizures.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking any medicines to prevent blood clots (such as warfarin, acenocoumarol).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have any heart or blood vessel conditions, including heart rhythm problems (arrhythmia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had a widespread rash, high body temperature and enlarged lymph nodes (drug reaction with eosinophilia and systemic symptoms or DRESS) or a severe skin rash or skin peeling, blistering and/or mouth sores (Stevens‑Johnson syndrome/toxic epidermal necrolysis or SJS/TEN) after taking Erleada or other related medicines.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p><strong>Falls and broken bones</strong></p><p>Falls have been observed in patients taking Erleada. Take extra care to reduce your risk of a fall. Broken bones have been observed in patients taking this medicine.</p><p>&nbsp;</p><p><strong>Heart disease, stroke, or mini-stroke</strong></p><p>Blockage of the arteries in the heart or in part of the brain that can lead to death has happened in some people during treatment with Erleada.</p><p>&nbsp;</p><p>Your healthcare provider will monitor you for signs and symptoms of heart or brain problems during your treatment with this medicine.</p><p>&nbsp;</p><p>Call your healthcare provider or go to the nearest emergency room right away if you get:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain or discomfort at rest or with activity, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness/paralysis in any part of the body, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in speaking.</p><p>&nbsp;</p><p>If you are taking any medicines, talk to your doctor or pharmacist to see if they are associated with an increased risk of seizure, bleeding or heart condition.</p><p>&nbsp;</p><p><strong>Severe Cutaneous Adverse Reactions (SCARs)</strong></p><p>Severe Cutaneous Adverse Reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS) or Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), have been reported with the use of Erleada. DRESS can appear as widespread rash, high body temperature and enlarged lymph nodes. SJS/TEN can appear initially as reddish target‑like spots or circular patches often with central blisters on the trunk. Also, ulcers of mouth, throat, nose, genitals and eyes (red and swollen eyes) can occur. These serious skin rashes are often preceded by fever and/or flu‑like symptoms. The rashes may progress to widespread peeling of the skin and life‑threatening complications or be fatal.</p><p>&nbsp;</p><p>If you develop a serious rash or another of these skin symptoms, stop taking this medicine and contact your doctor or seek medical attention immediately.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking this medicine. See section&nbsp;4 &lsquo;Serious side effects&rsquo; at the top of section 4 for more information.</p><p>&nbsp;</p><p><strong>Interstitial Lung Disease</strong></p><p>Cases of interstitial lung disease (non-infectious inflammation within the lungs that may lead to permanent damage) have been observed in patients taking Erleada, including fatal cases. The symptoms of interstitial lung disease are cough and shortness of breath sometimes with fever which are not caused by physical activity. Seek immediate medical attention, if you experience symptoms that may be signs of interstitial lung disease.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>This medicine is not for use in children and adolescents under 18&nbsp;years of age.</p><p>&nbsp;</p><p>If a child or young person accidentally takes this medicine:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; go to the hospital straight away</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take this package leaflet with you to show to the emergency doctor.</p><p>&nbsp;</p><p><strong>Other medicines and Erleada</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is because Erleada can affect the way some other medicines work. Also, some other medicines can affect the way Erleada works.</p><p>&nbsp;</p><p>In particular, tell your doctor if you are taking medicines that:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lower high fat levels in the blood (such as gemfibrozil)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat bacterial infections (such as moxifloxacin, clarithromycin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat fungal infections (such as itraconazole, ketoconazole)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat HIV infection (such as ritonavir, efavirenz, darunavir)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat anxiety (such as midazolam, diazepam)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat epilepsy (such as phenytoin, valproic acid)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat gastroesophageal reflux disease (conditions where there is too much acid in the stomach) (such as omeprazole)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prevent blood clots (such as warfarin, clopidogrel, dabigatran etexilate)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat hayfever and allergies (such as fexofenadine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lower cholesterol levels (such as &lsquo;statins&rsquo; such as rosuvastatin, simvastatin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat heart conditions or lower blood pressure (such as digoxin, felodipine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat heart rhythm problems (such as quinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat thyroid conditions (such as levothyroxine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat gout (such as colchicine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lower blood glucose (such as repaglinide)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat cancer (such as lapatinib, methotrexate)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat opioid addiction or pain (such as methadone)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat serious mental illnesses (such as haloperidol)</p><p>&nbsp;</p><p>You need to list the names of the medicines you take and show the list to your doctor or pharmacist when you start a new medicine. Mention to your doctor that you are taking Erleada if the doctor wants to start you on any new medicine. The dose of Erleada or any other medicines that you are taking may need to be changed.</p><p>&nbsp;</p><p><strong>Pregnancy and contraception information for men and women</strong></p><p>&nbsp;</p><p><strong>Information for women</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erleada must not be taken by women who are pregnant, may become pregnant, or who are breast-feeding. This medicine may harm your unborn baby.</p><p>&nbsp;</p><p><strong>Information for men &ndash; follow this advice during treatment and for 3&nbsp;months after stopping</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are having sex with a pregnant woman &ndash; use a condom to protect the unborn baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are having sex with a woman who can become pregnant ‑ use a condom and another highly effective method of contraception.</p><p>&nbsp;</p><p>Use contraception during treatment and for 3&nbsp;months after stopping. Talk to your doctor if you have any questions about contraception.</p><p>&nbsp;</p><p>This medicine may reduce male fertility.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Erleada is not likely to affect you being able to drive and use any tools or machines.</p><p>&nbsp;</p><p>The side effects for this medicine include seizures. If you are at higher risk of seizures (see Section&nbsp;2 &lsquo;Warnings and precautions&rsquo;), talk to your doctor.</p><p>&nbsp;</p><p><strong>Erleada contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 240&nbsp;mg dose (1&nbsp;tablet), that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Your doctor may also prescribe other medicines while you are taking Erleada.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>The recommended dose of this medicine is 240&nbsp;mg (one tablet) once a day.</p><p>&nbsp;</p><p><strong>Taking Erleada</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take this medicine by mouth.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take this medicine with food or between meals.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablet whole to make sure your full dose is taken. Do not crush or split the tablet.</p><p>&nbsp;</p><p><strong>If you cannot swallow the tablet whole</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you cannot swallow this medicine whole, you can:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Mix with one of the following non‑fizzy beverages or soft foods; orange juice, green tea, applesauce, or drinkable yogurt as follows:</strong></p><p>&sect;&nbsp;&nbsp;&nbsp; Place the whole tablet in a cup. Do not crush or split the tablet.</p><p>&sect;&nbsp;&nbsp;&nbsp; Add about 10&nbsp;mL (2&nbsp;teaspoons) of non‑fizzy water to make sure that the tablet is completely in water.</p><p>&sect;&nbsp;&nbsp;&nbsp; Wait 2&nbsp;minutes until the tablet is broken up and spread out, then stir the mixture.</p><p>&sect;&nbsp;&nbsp;&nbsp; Add in 30&nbsp;mL (6&nbsp;teaspoons or 2&nbsp;tablespoons) of one of the following non‑fizzy beverages or soft foods: orange juice, green tea, applesauce, or drinkable yogurt and stir the mixture.</p><p>&sect;&nbsp;&nbsp;&nbsp; Swallow the mixture immediately.</p><p>&sect;&nbsp;&nbsp;&nbsp; Rinse the cup with enough water to make sure the whole dose is taken and drink it immediately.</p><p>&sect;&nbsp;&nbsp;&nbsp; Do not save the medicine/food mixture for later use.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Feeding tube:</strong> This medicine may also be given through certain feeding tubes. Ask your healthcare provider for specific instructions on how to properly take the tablet through a feeding tube.</p><p>&nbsp;</p><p><strong>If you take more Erleada than you should</strong></p><p>If you take more than you should, stop taking this medicine and contact your doctor. You may have an increased risk of side effects.</p><p>&nbsp;</p><p><strong>If you forget to take Erleada</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take this medicine, take your usual dose as soon as you remember on the same day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take this medicine for the whole day ‑ take your usual dose the following day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take this medicine for more than one day ‑ talk to your doctor straight away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Erleada</strong></p><p>Do not stop taking this medicine without checking with your doctor first.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p><strong>Stop taking Erleada and seek medical attention immediately if you notice any of the following symptoms:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; widespread rash, high body temperature and enlarged lymph nodes (drug reaction with eosinophilia and systemic symptoms or DRESS)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (Stevens‑Johnson syndrome, toxic epidermal necrolysis).</p><p>&nbsp;</p><p>Tell your doctor straight away if you notice any of the following serious side effects &ndash; your doctor may stop treatment:</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Very common</strong>: may affect more than 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; falls or fractures (broken bones). Your healthcare provider may monitor you more closely if you are at risk for fractures.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Common</strong>: may affect up to 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart disease, stroke, or mini-stroke. Your healthcare provider will monitor you for signs and symptoms of heart or brain problems during your treatment. Call your healthcare provider or go to the nearest emergency room right away if you get chest pain or discomfort at rest or with activity, or shortness of breath, or if you get muscle weakness/paralysis in any part of the body, or difficulty in speaking during your treatment with Erleada.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Uncommon</strong>: may affect up to 1 in 100 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fit or seizure. Your healthcare provider will stop this medicine if you have a seizure during treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; restless legs syndrome (urges to move the legs to stop painful or odd sensations, often occurring at night).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Not known</strong>: frequency cannot be estimated from the available data</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing and shortness of breath, possibly accompanied by fever, that is not brought on by physical activity (inflammation within the lungs, known as interstitial lung disease).</p><p>&nbsp;</p><p>Tell your healthcare provider right away if you notice any of the serious side effects above.</p><p>&nbsp;</p><p><strong>Side effects include</strong></p><p>Tell your healthcare provider if you notice any of the following side effects:</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hot flush</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; broken bones</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; falls</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss.</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in sense of taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood test showing high level of cholesterol in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood test showing high level of a type of fat called &ldquo;triglycerides&rdquo; in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke or mini-stroke caused by low blood flow to part of the brain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; under‑active thyroid which can make you feel more tired and have difficulty getting started in the morning, and blood tests may also show an under-active thyroid.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures/fits.</p><p>&nbsp;</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal heart tracing on an ECG (electrocardiogram)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; widespread rash, high body temperature and enlarged lymph nodes (drug reaction with eosinophilia and systemic symptoms or DRESS)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reddish non‑elevated, target‑like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes, which can be preceded by fever and flu‑like symptoms. These serious skin rashes can be potentially life‑threatening (Stevens‑Johnson syndrome, toxic epidermal necrolysis).</p><p>&nbsp;</p><p>Tell your healthcare provider if you notice any of the side effects listed above.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the container (blister foils, inner wallet, outer wallet, bottle, and carton) after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in the original package in order to protect from moisture. Store below 30&deg;C.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is apalutamide. Each film‑coated tablet contains 240&nbsp;mg of apalutamide.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients of the tablet core are colloidal anhydrous silica, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, and silicified microcrystalline cellulose. The film‑coating contains glycerol monocaprylocaprate, iron oxide black (E172), poly (vinyl alcohol), talc, titanium dioxide (E171), and macrogol poly (vinyl alcohol) grafted copolymer (see section&nbsp;2, Erleada contains sodium).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Erleada film-coated tablets are bluish grey to grey, oval shaped, film coated tablets (21 mm long x 10 mm wide), with “E240” written on one side.
	
The tablets may be supplied either in a bottle or in a wallet pack. Not all pack types and sizes may be marketed.

Bottle
The tablets are supplied in a plastic bottle with a child resistant closure. Each bottle contains 30 tablets and a total of 2 g of desiccant. Each carton contains one bottle. Store in the original package. Do not swallow or discard desiccant.

28 day carton
Each 28 day carton contains 28 film coated tablets in 2 cardboard wallet packs of 14 film coated tablets each.

30 day carton
Each 30 day carton contains 30 film coated tablets in 3 cardboard wallet packs of 10 film coated tablets each.
	
	Not all pack types and sizes may be marketed 
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Janssen‑Cilag International NV</p><p>Turnhoutseweg 30</p><p>B‑2340 Beerse</p><p>Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Catalent Pharma Solutions, LLC</p><p>1100 Enterprise Drive,</p><p>Winchester, 40391 Kentucky (KY), US</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	To contact us, go to www.janssen.com/contact-us
	
	This leaflet was last revised in 7 December 2023. 

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو</strong> <strong>دواء إرليدا</strong></p><p dir="RTL">إرليدا هو دواء لعلاج السرطان يحتوي على المادة الفعالة &quot;أبالوتاميد&quot;.</p><p>&nbsp;</p><p dir="RTL"><strong>ما</strong><strong> </strong><strong>هي دواعي استعمال دواء إرليدا</strong></p><p dir="RTL">يُستخدم إرليدا لعلاج الرجال البالغين المصابين بسرطان البروستاتا الذي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتقل إلى أجزاء أخرى من الجسم ولا يزال يستجيب لطرق العلاج الطبية أو الجراحية التي تخفض من هرمون التستوستيرون (ويسمى أيضًا سرطان البروستاتا الحساس للهرمونات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم ينتقل إلى أجزاء أخرى من الجسم، ولم يعد يستجيب للعلاج الطبي أو الجراحي الذي يخفض هرمون التستوستيرون (يطلق عليه أيضًا سرطان البروستاتا المقاوم للإخصاء).</p><p>&nbsp;</p><p dir="RTL"><strong>كيف يعمل دواء إرليدا</strong></p><p dir="RTL">يعمل دواء إرليدا من خلال إيقاف نشاط هرمونات تسمى الأندروجينات (مثل التستوستيرون). قد تتسبب الأندروجينات في نمو السرطان. من خلال إيقاف تأثير الأندروجينات، يعمل أبالوتاميد على إيقاف نمو وانقسام خلايا سرطان البروستاتا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول دواء إرليدا في الحالات التالية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه مادة الأبالوتاميد أو أي من المكونات الأخرى في هذا الدواء (مدرجة في القسم&nbsp;6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ امرأة حاملاً أو قد تصبحين حاملاً )راجعي قسم الحمل ومنع الحمل أدناه لمزيد من المعلومات).</p><p>&nbsp;</p><p dir="RTL">لا تتناول هذا الدواء إذا كانت أي من الحالات المذكورة أعلاه تنطبق عليك. إذا لم تكن متأكدًا، فاستشر طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">استشر طبيبك أو الصيدلي قبل تناول هذا الدواء:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا سبق لك أن تعرضت لنوبات صرع أو تشنجات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أي أدوية لمنع تجلط الدم (مثل وارفارين، أسينوكومارول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أي أمراض في القلب أو الأوعية الدموية، بما في ذلك مشاكل في ضربات القلب (عدم انتظام ضربات القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبق أن عانيت من طفح جلدي واسع الانتشار وارتفاع درجة حرارة الجسم وتضخم الغدد الليمفاوية (متلازمة رد الفعل الدوائي مع فرط الحمضات والأعراض الجهازية &quot;DRESS&quot;) أو طفح جلدي شديد أو تقشير الجلد، ظهور بثور وتقرحات في الفم أو كلتيهما (متلازمة ستيفن جونسون والنخر البشرويّ السُّمّي أو ما يُطلق عليهما SJS/TEN) بعد تناول دواء إرليدا أو أدوية أخرى ذات صلة.</p><p>&nbsp;</p><p dir="RTL">إذا كانت أي من الحالات المذكورة أعلاه تنطبق عليك (أو إذا لم تكن متأكدًا)، فاستشر طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>السقوط وكسر العظام</strong></p><p dir="RTL">لقد لوحظ حدوث حالات سقوط للمرضى الذين يتناولون دواء إرليدا. توخ المزيد من الحذر لتقليل خطر السقوط. لوحظ حدوث حالات كسور بالعظام لدى المرضى الذين يتناولون هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>أمراض القلب أو السكتة الدماغية أو السكتة الدماغية البسيطة</strong></p><p dir="RTL">لقد لوحظ حدوث حالات انسداد في شرايين القلب أو في جزء من المخ، التي قد تؤدي إلى الوفاة مع بعض الأشخاص فترة تلقي العلاج بدواء إرليدا.</p><p>&nbsp;</p><p dir="RTL">سوف يتابع مقدم الرعاية الصحية الخاص بك ظهور أي علامات أو أعراض مشاكل في القلب أو المخ أثناء فترة تلقي العلاج بهذا دواء.</p><p>&nbsp;</p><p dir="RTL">اتصل بمقدم الرعاية الصحية الخاص بك أو اذهب إلى أقرب غرفة طوارئ على الفور إذا شعرت بأعراض مثل:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ألم في الصدر أو عدم الراحة أثناء فترات الراحة أو أثناء النشاط، أو</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ضيق التنفس، أو</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ضعف/ شلل العضلات في أي جزء من الجسم، أو</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>صعوبة في التحدث.</p><p>&nbsp;</p><p dir="RTL">إذا كنت تتناول أي أدوية، فاستشر طبيبك أو الصيدلي لمعرفة ما إذا كانت مرتبطة بزيادة خطر التعرض لنوبات صرع، أو النزيف، أو أمراض القلب.</p><p>&nbsp;</p><p><strong>ردود فعل سلبية جلدية شديدة(SCARs)</strong></p><p dir="RTL">تم الإبلاغ عن ردود فعل سلبية جلدية شديدة(SCARs)، بما في ذلك متلازمة رد الفعل الدوائي مع فرط الحمضات والأعراض الجهازية &quot;DRESS&quot; أو متلازمة ستيفن جونسون والنخر البشرويّ السُّمّي(SJS/TEN)، عند استعمال دواء إرليدا. يمكن أن تظهر أعراض متلازمة رد الفعل الدوائي مع فرط الحمضات والأعراض الجهازية &quot;DRESS&quot; على شكل طفح جلدي واسع الانتشار وارتفاع في درجة حرارة الجسم وتضخم في الغدد الليمفاوية. قد يظهر متلازمة ستيفن جونسون/ النخر البشرويّ السُّمّي (SJS/TEN)&rlm; في البداية كبقع حمراء تشبه الأهداف أو بقع دائرية مع بثور مركزية على الجذع. قد تحدث أيضًا قرح بالفم والحلق والأنف والأعضاء التناسلية والعينين (احمرار العينين وتورمهما). غالبًا ما يسبق هذه الطفح الجلدي الخطير حمى و/أو أعراض تشبه أعراض الأنفلونزا. قد يتطور الطفح الجلدي إلى تقشير واسع النطاق للجلد ومضاعفات تهدد الحياة أو قد تكون مميتة .</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ظهر لديك طفح جلدي خطير أو غيره من الأعراض الجلدية، فتوقف عن تناول هذا الدواء واتصل بطبيبك أو اطلب العناية الطبية على الفور.</p><p>&nbsp;</p><p dir="RTL">إذا كانت أي من الحالات المذكورة أعلاه تنطبق عليك (أو إذا لم تكن متأكدًا)، فاستشر طبيبك أو الصيدلي قبل تناول هذا الدواء. راجع القسم (4) &quot;الأعراض الجانبية الخطيرة&quot; في أعلى القسم (4) لمزيد من المعلومات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مرض الرئة الخلالي</strong></p><p dir="RTL">تمت ملاحظة حالات مرض الرئة الخلالي (التهاب غير مُعْدٍ داخل الرئتين قد يؤدي إلى ضرر دائم) في حالات المرضى الذين يتناولون إرليدا، بما في ذلك حالات الوفاة. أعراض مرض الرئة الخلالي هي السعال وضيق التنفس المصحوب أحيانًا بالحمى التي لا تحدث بسبب النشاط البدني. التمس العناية الطبية الفورية، إذا كنت تعاني من أعراض قد تكون علامات على الإصابة بمرض الرئة الخلالي.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">هذا الدواء غير مخصص للاستخدام مع الأطفال والمراهقين دون سن&nbsp;18 عامًا.</p><p>&nbsp;</p><p dir="RTL">في حالة تناول طفل أو شاب صغير لهذا الدواء عن طريق الخطأ:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توجّه إلى المستشفى على الفور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خذ معك نشرة العبوة هذه لعرضها على طبيب الطوارئ.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى ودواء إرليدا</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. هذا لأن دواء إرليدا يمكنه أن يؤثر على مفعول بعض الأدوية الأخرى. أيضًا، يمكن لبعض الأدوية الأخرى أن تؤثر على مفعول دواء إرليدا.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أدوية للحالات التالية تحديدًا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفض مستويات الدهون المرتفعة في الدم (مثل جيمفيبروزيل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج العدوى البكتيرية (مثل موكسيفلوكساسين، كلاريثرومايسين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج العدوى الفطرية (مثل إيتراكونازول، كيتوكونازول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج عدوى فيروس نقص المناعة البشرية (مثل ريتونافير، إيفافيرينز، دارونافير)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج القلق (مثل ميدازولام، ديازيبام)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج الصرع (مثل فينيتوين، حمض الفالبرويك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج مرض الارتجاع المعدي المريئي (حالات تكون فيها كمية الحمض في المعدة كبيرة جدًا) (مثل أوميبرازول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوقاية من الجلطات الدموية (مثل وارفارين، كلوبدوجريل، دابيجاتران إتيكسيلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج حمى القش وأنواع الحساسية (مثل فيكسوفينادين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفض مستويات الكوليسترول (مثل &quot;الستاتينات&quot; مثل رسيوفاستاتين وسيمفاستاتين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج أمراض القلب أو خفض ضغط الدم (مثل ديجوكسين، فيلوديبين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج مشاكل ضربات القلب (مثل كينيدين، ديسوبيراميد، أميودارون، سوتالول، دوفتيليد، إيبوتليد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج أمراض الغدة الدرقية (مثل ليفوثيروكسين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج النقرس (مثل كولشيسين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفض نسبة الجلوكوز في الدم (مثل ريباجلينيد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج السرطان (مثل لاباتينيب، ميثوتريكسات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج إدمان المواد الأفيونية أو الألم (مثل ميثادون)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج الأمراض النفسية الخطيرة (مثل هالوبيريدول)</p><p>&nbsp;</p><p dir="RTL">أنت بحاجة إلى إعداد قائمة بالأدوية التي تتناولها وعرض هذه القائمة على طبيبك أو الصيدلي عند بدء دواء جديد. أخبر طبيبك أنك تتناول دواء إرليدا إذا كان الطبيب يريد بدء علاجك باستخدام أي دواء جديد. قد يلزم تغيير جرعة دواء إرليدا أو أي أدوية أخرى تتناولها.</p><p>&nbsp;</p><p dir="RTL"><strong>معلومات عن الحمل ووسائل منع الحمل للرجال والسيدات</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>معلومات للسيدات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم تناول دواء إرليدا من قبل النساء الحوامل أو اللاتي قد يصبحن حوامل أو تقوم بالرضاعة الطبيعية. قد يضر هذا الدواء بجنينك.</p><p>&nbsp;</p><p dir="RTL"><strong>معلومات للرجال - اتبع هذه النصيحة أثناء العلاج ولمدة 3&nbsp;أشهر بعد إيقافه</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة المعاشرة الزوجية لزوجتك أثناء الحمل، استخدم واقيًا ذكريًا لحماية الجنين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة المعاشرة الزوجية لزوجتك التي يمكن أن تصبح حاملا، استخدم واقيًا ذكريًا ووسيلة أخرى عالية الفعالية لمنع الحمل.</p><p>&nbsp;</p><p dir="RTL">استخدم وسائل منع الحمل أثناء العلاج ولمدة 3&nbsp;أشهر بعد إيقافه. استشر طبيبك إذا كانت لديك أي أسئلة تتعلق بوسائل منع الحمل.</p><p>&nbsp;</p><p dir="RTL">قد يقلل هذا الدواء من خصوبة الرجال.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثر إرليدا على قدرتك على القيادة أو استخدام أي أدوات أو آلات.</p><p>&nbsp;</p><p dir="RTL">لآثار الجانبية لهذا الدواء تشمل نوبات صرع. استشر طبيبك إذا كنت أكثرعرضة لخطر حدوث نوبات صرع (انظر القسم&nbsp;2 تحذيرات واحتياطات).</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي دواء إرليدا على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1&nbsp;ملليمول صوديوم (23&nbsp;مجم) لكل جرعة 240&nbsp;مجم (للقرص&nbsp;الواحد)؛ أي أن هذا الدواء يُعد &quot;خاليًا من الصوديوم&quot; بشكل أساسي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائمًا كما أخبرك الطبيب تمامًا. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p>&nbsp;</p><p dir="RTL">قد يصف لك طبيبك كذلك أدوية أخرى أثناء تناولك دواء إرليدا.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة الدوائية</strong></p><p dir="RTL">الجرعة الموصى بها لهذا الدواء هي 240&nbsp;مجم (قرص واحد) مرة واحدة يوميًا.</p><p>&nbsp;</p><p dir="RTL"><strong>استعمال دواء إرليدا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول هذا الدواء عن طريق الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول هذا الدواء مع الطعام أو بين الوجبات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع القرص بالكامل للتأكد من تناول جرعتك كاملةً. لا تسحق القرص أو تقسّمه.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا لم تتمكن من بلع القرص كاملاً</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تتمكن من بلع هذا الدواء بالكامل، يمكنك:</p><p dir="RTL"><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مزجه بأحد المشروبات غير الغازية أو الأطعمة اللينة التالية</strong><strong>؛</strong><strong> </strong><strong>عصير البرتقال أو الشاي الأخضر أو عصير التفاح أو مشروب الزبادي، على النحو التالي:</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع القرص كاملاً في كوب. لا تسحق القرص أو تقسّمه.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أضف حوالي 10&nbsp;مل (ملعقتين&nbsp;صغيرتين) من الماء غير الفوار للتأكد من غمر القرص بالكامل في الماء.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتظر&nbsp;دقيقتين حتى ينكسر القرص ويذوب بالكامل، ثم حرِّك المزيج.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أضف 30&nbsp;مل (6&nbsp;ملاعق صغيرة أو&nbsp;ملعقتين كبيرتين) من أحد المشروبات غير الغازية أو الأطعمة اللينة التالية: عصير البرتقال أو الشاي الأخضر أو عصير التفاح أو مشروب الزبادي، ثم حرِّك المزيج.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع المزيج على الفور.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اشطف الكوب بكمية كافية من الماء للتأكد من تناول الجرعة كاملة واشربها على الفور.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تحفظ مزيج الدواء/ الطعام لاستخدامه لاحقًا.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أنبوب التغذية:</strong> يمكن أيضًا تناول هذا الدواء من خلال أنابيب تغذية معينة. اطلب من مقدم الرعاية الصحية الخاص بك الحصول على تعليمات محددة بشأن كيفية تناول القرص بطريقة صحيحة عن طريق أنبوب التغذية.</p><p>&nbsp;</p><p dir="RTL"><strong>في حالة تناول جرعة زائدة من دواء إرليدا</strong></p><p dir="RTL">إذا تناولت جرعة زائدة، فتوقف عن تناول دواء إرليدا واتصل بطبيبك. قد تكون معرضًا لزيادة خطر الإصابة بالأعراض الجانبية.</p><p>&nbsp;</p><p dir="RTL"><strong>في حالة نسيان تناول دواء إرليدا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت تناول هذا الدواء، فتناول جرعتك المعتادة بمجرد أن تتذكرها في نفس اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة نسيان تناول هذا الدواء طوال اليوم، تناول جرعتك المعتادة في اليوم التالي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة نسيان تناول هذا الدواء لأكثر من يوم واحد، فاستشر طبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة لتعويض جرعة منسية.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول دواء إرليدا</strong></p><p dir="RTL">لا تتوقف عن تناول هذا الدواء دون استشارة طبيبك أولًا.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية بشأن استخدام هذا الدواء، فاطرحها على طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية على الرغم من عدم إصابة الجميع بها.</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة</strong></p><p dir="RTL"><strong>توقف عن تناول دواء إرليدا</strong><strong> </strong><strong>واطلب العناية الطبية على الفور إذا لاحظت أيًا من الأعراض الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي واسع الانتشار وارتفاع درجة حرارة الجسم وتضخم الغدد الليمفاوية (متلازمة رد الفعل الدوائي مع فرط الحمضات والأعراض الجهازية أو&quot;DRESS&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهوربقع حمراء غير مرتفعة تشبه الأهداف أو بقع دائرية مع بثور مركزية على الجذع، وتقشير الجلد، وقرح بالفم والحلق والأنف والأعضاء التناسلية والعينين. يمكن أن يسبق هذا الطفح الجلدي الخطير حمى وأعراض تشبه الإنفلونزا (متلازمة ستيفن جونسون/ النخر البشرويّ السُّمّي (SJS/TEN).</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت أيًا من الآثار الجانبية التالية الخطيرة - قد يقوم الطبيب بإيقاف العلاج:</p><p dir="RTL"><strong>شائعة جدًا</strong>: قد تؤثر في أكثر من شخص واحد من كل 10 أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السقوط أو الكسور (كسور العظام). قد يقوم مقدم الرعاية الصحية الخاص بك بمراقبتك عن كثب إذا كنت معرضًا لخطر الإصابة بالكسور.</p><p dir="RTL"><strong>شائعة</strong>: قد تؤثر في شخص واحد من كل 10 أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض القلب أو السكتة الدماغية أو السكتة الدماغية البسيطة. سوف يتابع مقدم الرعاية الصحية الخاص بك ظهور أي علامات أو أعراض مشاكل القلب أو المخ أثناء فترة تلقي علاجك. اتصل بمقدم الرعاية الصحية أو اذهب إلى أقرب غرفة طوارئ على الفور إذا شعرت بألم في الصدر أو عدم راحة أثناء فترات الراحة أو مع ممارسة نشاط أو حدوث ضيق في التنفس أو إذا شعرت بضعف في العضلات/شلل في أي جزء من الجسم، أو صعوبة في التحدث أثناء فترة تلقي العلاج بدواء إرليدا.</p><p dir="RTL"><strong>غير شائعة</strong>: قد تؤثر في شخص واحد من كل 100 شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج أو نوبة صرع. سيقوم مقدم الرعاية الصحية الخاص بك بإيقاف هذا الدواء إذا تعرضت لنوبة صرع أثناء العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة تململ الساقين (الرغبة في تحريك الساقين لوقف الأحاسيس المؤلمة أو الغريبة، التي تحدث غالبًا في الليل).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف</strong>: لا يمكن تقدير معدل التكرار من خلال البيانات المتاحة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال وضيق التنفس، ربما يكون مصحوبًا بحمى ليست ناتجة عن النشاط البدني (التهاب داخل الرئتين، معروف باسم مرض الرئة الخلالي).</p><p>&nbsp;</p><p dir="RTL">أخبر مقدم الرعاية الصحية الخاص بك على الفور إذا لاحظت أيًا من الأعراض الجانبية الخطيرة المذكورة أعلاه.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>تشمل الأعراض الجانبية</strong></p><p dir="RTL">أخبر مقدم الرعاية الصحية الخاص بك إذا لاحظت أيًا من الأعراض الجانبية التالية:</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة جدًا </strong>(قد تؤثر في أكثر من شخص واحد من كل 10&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب الشديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبات الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كسور العظام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السقوط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن.</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة </strong>(قد يؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص ):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في حاسة التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبار دم يبين ارتفاع مستوى الكوليسترول في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبار دم يبين ارتفاع مستوى نوع من الدهون يسمى &quot;الدهون الثلاثية&quot; في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة الدماغية أو السكتة الدماغية البسيطة الناجمة عن انخفاض تدفق الدم إلى جزء من المخ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نشاط الغدة الدرقية الذي قد يجعلك تشعر بمزيد من التعب وصعوبة في النهوض صباحًا، وقد تبين اختبارات الدم أيضًا حدوث انخفاض في نشاط الغدة الدرقية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير شائعة </strong><strong>(</strong>قد يؤثر على ما يصل إلى شخص واحد من كل<strong> </strong>100<strong> </strong>شخص<strong>):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات صرع/ التشنجات.</p><p>&nbsp;</p><p dir="RTL"><strong>غير معروفة </strong>(لا يمكن تقدير معدل التكرار من البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتبع غير طبيعي للقلب على ECG (مخطط كهربية القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي واسع الانتشار وارتفاع درجة حرارة الجسم وتضخم الغدد الليمفاوية (متلازمة رد الفعل الدوائي مع فرط الحمضات والأعراض الجهازية أو&quot;DRESS&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور بقع حمراء غير مرتفعة تشبه الأهداف أو بقع دائرية مع بثور مركزية على الجذع في كثير من الأحيان، وتقشير الجلد، وقرح بالفم والحلق والأنف والأعضاء التناسلية والعينين، والتي قد يسبقها حدوث حمى أو أعراض تشبه الأنفلوانزا. يمكن أن يكون هذه الطفح الجلدي الخطير مهددًا للحياة (متلازمة ستيفن جونسون/ النخر البشرويّ السُّمّي).</p><p>&nbsp;</p><p dir="RTL">أخبر مقدم الرعاية الصحية الخاص بك إذا لاحظت أيًا من الأعراض الجانبية المذكورة أعلاه.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ&nbsp; طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة (أشرطة رقائق الألومنيوم والحافظة الداخلية والحافظة الخارجية والزجاجة والعبوة الكرتونية) بعد الحروف EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p>&nbsp;</p><p dir="RTL">تُخزّن في العبوة الأصلية لحمايتها من الرطوبة. يُحفَظ في درجة حرارة أقل من 30 درجة مئوية.</p><p>&nbsp;</p><p dir="RTL">يُحظر التخلص من أي أدوية عبر إلقائها في مياه المجاري أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعُد تستخدمها. وستساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات دواء إرليدا</strong></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة هي أبالوتاميد. يحتوي كل قرص مغلّف بطبقة رقيقة على 240&nbsp;مجم من مادة أبالوتاميد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى للمادة الأساسية للقرص هي السيليكا اللامائية الغروانية وكروس كارميلوز الصوديوم وسكسينات أسيتات الهيبروميلوز وستيارات المغنيسيوم وسيليلوز بلوري مكروي مُسَلْكَت. تحتوي طبقة المُغلّفة للقرص على مونوكابريلوكابرات الجلسرين وأكسيد الحديد الأسود (E172) والبولي (كحول الفينيل) والتلك وثاني أكسيد التيتانيوم (E171) وماكروغول بولي (كحول الفينيل) كوبوليمر مطعم (انظر القسم 2، يحتوي دواء إرليدا على الصوديوم).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما شكل دواء إرليدا وما محتويات العبوة</strong></p><p dir="RTL">أقراص إرليدا المغلفة بطبقة رقيقة ذات لون رمادي مزرق يميل إلى الرمادي، بيضاوية الشكل، مغلفة بطبقة رقيقة (21&nbsp;مم&nbsp;طول&nbsp;&times;&nbsp;10&nbsp;مم عرض)، مكتوب على أحد جانبي القرص &quot;E240&quot;.</p><p>&nbsp;</p><p dir="RTL">قد يتم تقديم الأقراص في زجاجة أو عبوة حافظة. قد لا تتوفر العبوات من جميع الأشكال والأحجام بالسوق.</p><p>&nbsp;</p><p dir="RTL"><strong>الزجاجة</strong></p><p dir="RTL">تُوفَّر الأقراص في زجاجة بلاستيكية مزودة بغطاء مقاوم لعبث الأطفال. تحتوي كل زجاجة على 30&nbsp;قرصًا وما مجموعه 2 جم من المادة المجفِّفة. كل علبة كرتونية تحتوي على زجاجة واحدة. يُخزَّن في العبوة الأصلية. لا تبلع المادة المجففة أو تتخلص منها.</p><p>&nbsp;</p><p dir="RTL"><strong>عبوة كرتونية تكفي 28 يومًا</strong></p><p dir="RTL">تحتوي كل عبوة كرتونية مخصصة لعلاج 28 يومًا على 28&nbsp;قرصًا مغلفًا بطبقة رقيقة في عبوتين حافظتين&nbsp;من الورق المقوى، في كل منها 14&nbsp;قرصًا مغلفًا بطبقة رقيقة.</p><p>&nbsp;</p><p dir="RTL"><strong>عبوة كرتونية تكفي 30 يومًا</strong></p><p dir="RTL">تحتوي كل عبوة كرتونية مخصصة لعلاج 30 يومًا على 30&nbsp;قرصًا مغلفًا بطبقة رقيقة في 3 عبوات حافظة&nbsp;من الورق المقوى، في كل منها 10&nbsp;أقراص مغلفة بطبقة رقيقة.</p><p>&nbsp;</p><p dir="RTL">قد لا تتوفر العبوات من جميع الأشكال والأحجام بالسوق.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل الرخصة التسويقية</strong></p><p dir="RTL">جانسن سيلاج الدولية إن في</p><p dir="RTL">ترنهوتسويج 30</p><p dir="RTL">بي-2340 بيرس</p><p dir="RTL">بلجيكا</p><p>&nbsp;</p><p dir="RTL"><strong>الشركة المصنّعة</strong></p><p dir="RTL">كاتالنت فارما سوليوشنز، إل إل سي</p><p dir="RTL">&nbsp;1100 إنتربرايز درايف،</p><p dir="RTL">وينشستر، 40391 كنتاكي (KY)،</p><p dir="RTL">الولايات المتحدة</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            للتواصل معنا، يُرجى زيارة موقعنا الإلكتروني www.janssen.com/contact-us

	تمت آخر مراجعة لهذه النشرة في 7 ديسمبر 2023.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Erleada 240 mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains 240 mg of apalutamide.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

Bluish grey to grey, oval shaped, film coated tablets (21 mm long x 10 mm wide), debossed with “E240” on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Erleada is indicated:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in adult men for the treatment of non‑metastatic castration‑resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section&nbsp;5.1).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT) (see section&nbsp;5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with apalutamide should be initiated and supervised by specialist physicians experienced in the medical treatment of prostate cancer.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose is 240&nbsp;mg (one 240&nbsp;mg tablet) as an oral single daily dose.</p><p>&nbsp;</p><p>Medical castration with gonadotropin releasing hormone analogue (GnRHa) should be continued during treatment in patients not surgically castrated.</p><p>&nbsp;</p><p>If a dose is missed, it should be taken as soon as possible on the same day with a return to the normal schedule the following day. Extra tablets should not be taken to make up the missed dose.</p><p>&nbsp;</p><p>If a &ge;&nbsp;Grade&nbsp;3 toxicity or an intolerable adverse reaction is experienced by the patient, dosing should be held rather than permanently discontinuing treatment until symptoms improve to &le;&nbsp;Grade&nbsp;1 or original grade, then should be resumed at the same dose or a reduced dose (180&nbsp;mg or 120&nbsp;mg), if warranted. For the most common adverse reactions, (see section&nbsp;4.8).</p><p>&nbsp;</p><p><em>Special populations</em></p><p><em>&nbsp;</em></p><p><em><u>Elderly</u></em></p><p>&nbsp;</p><p>No dose adjustment is necessary for elderly patients (see sections&nbsp;5.1 and 5.2).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>&nbsp;</p><p>No dose adjustment is necessary for patients with mild to moderate renal impairment.</p><p>&nbsp;</p><p>Caution is required in patients with severe renal impairment as apalutamide has not been studied in this patient population (see section&nbsp;5.2). If treatment is started, patients should be monitored for the adverse reactions listed in section&nbsp;4.8 and dose reduce as per section&nbsp;4.2&nbsp;Posology and method of administration.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>&nbsp;</p><p>No dose adjustment is necessary for patients with baseline mild or moderate hepatic impairment (Child‑Pugh Class A and B, respectively).</p><p>&nbsp;</p><p>Erleada is not recommended in patients with severe hepatic impairment as there are no data in this patient population and apalutamide is primarily hepatically eliminated (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>&nbsp;</p><p>There is no relevant use of apalutamide in the paediatric population.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Oral use.</p><p>The tablet should be swallowed whole to ensure that the full intended dose is taken. The tablet should not be crushed or split. The tablet can be taken with or without food.</p><p>&nbsp;</p><p><em>Taking Erleada with non‑fizzy beverage or soft food</em></p><p>&nbsp;</p><p>For patients who cannot swallow the tablet whole, Erleada can be dispersed in non‑fizzy water and then mixed with one of the following non‑fizzy beverages or soft foods; orange juice, green tea, applesauce, or drinkable yogurt as follows:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place the whole Erleada 240&nbsp;mg tablet in a cup. Do not crush or split the tablet.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add about 10&nbsp;mL (2&nbsp;teaspoons) of non‑fizzy water to make sure that the tablet is completely in water.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wait 2&nbsp;minutes until the tablet is broken up and spread out, then stir the mixture.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add in 30&nbsp;mL (6&nbsp;teaspoons or 2&nbsp;tablespoons) of one of the following non‑fizzy beverages or soft foods; orange juice, green tea, applesauce, or drinkable yogurt and stir the mixture.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the mixture immediately.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rinse the cup with enough water to make sure the whole dose is taken and drink it immediately.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not save the medicinal product/food mixture for later use.</p><p>&nbsp;</p><p><em>Administration by nasogastric feeding tube</em></p><p>&nbsp;</p><p>Erleada 240&nbsp;mg tablet can also be administered through a nasogastric feeding tube (NG tube) 8&nbsp;French or greater as follows:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place one 240&nbsp;mg tablet in the barrel of a syringe (use at least a 20&nbsp;mL syringe) and draw up 10&nbsp;mL of non‑carbonated water into the syringe.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wait 10&nbsp;minutes and then shake vigorously to disperse the contents completely.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer immediately through the NG feeding tube.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Refill the syringe with non‑carbonated water and administer. Repeat until no tablet residue is left in the syringe or feeding tube.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Women who are or may become pregnant (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Seizure</u></p><p>&nbsp;</p><p>Erleada is not recommended in patients with a history of seizures or other predisposing factors including, but not limited to, underlying brain injury, recent stroke (within one year), primary brain tumours or brain metastases. If a seizure develops during treatment with Erleada, treatment should be discontinued permanently. The risk of seizure may be increased in patients receiving concomitant medicinal products that lower the seizure threshold.</p><p>&nbsp;</p><p>In two randomised studies (SPARTAN and TITAN), seizure occurred in 0.6% of patients receiving apalutamide and in 0.2% of patients treated with placebo. These studies excluded patients with a history of seizure or predisposing factors for seizure.</p><p>&nbsp;</p><p>There is no clinical experience in re‑administering Erleada to patients who experienced a seizure.</p><p>&nbsp;</p><p><u>Falls and fractures</u></p><p>&nbsp;</p><p>Falls and fractures occurred in patients receiving apalutamide (see section&nbsp;4.8). Patients should be evaluated for fracture and fall risk before starting Erleada and should continue to be monitored and managed according to established treatment guidelines and use of bone-targeted agents should be considered.</p><p><u>&nbsp;</u></p><p><u>Ischaemic heart disease and ischaemic cerebrovascular disorders</u></p><p>&nbsp;</p><p>Ischaemic heart disease and ischaemic cerebrovascular disorders, including events leading to death, occurred in patients treated with apalutamide (see section&nbsp;4.8). The majority of patients had cardiac/cerebrovascular ischaemic disease risk factors. Patients should be monitored for signs and symptoms of ischaemic heart disease and ischaemic cerebrovascular disorders. Management of risk factors, such as hypertension, diabetes, or dyslipidaemia should be optimised as per standard of care.</p><p><u>&nbsp;</u></p><p><u>Concomitant use with other medicinal products </u></p><p>&nbsp;</p><p>Apalutamide is a potent enzyme inducer and may lead to loss of efficacy of many commonly used medicinal products (see section&nbsp;4.5). A review of concomitant medicinal products should therefore be conducted when apalutamide treatment is initiated. Concomitant use of apalutamide with medicinal products that are sensitive substrates of many metabolising enzymes or transporters (see section&nbsp;4.5) should generally be avoided if their therapeutic effect is of large importance to the patient, and if dose adjustments cannot easily be performed based on monitoring of efficacy or plasma concentrations.</p><p>&nbsp;</p><p>Co‑administration of apalutamide with warfarin and coumarin-like anticoagulants should be avoided. If Erleada is co‑administered with an anticoagulant metabolised by CYP2C9 (such as warfarin or acenocoumarol), additional International Normalised Ratio (INR) monitoring should be conducted (see section&nbsp;4.5).</p><p><u>&nbsp;</u></p><p><u>Recent cardiovascular disease</u></p><p>&nbsp;</p><p>Patients with clinically significant cardiovascular disease in the past 6 months including severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischaemic attacks), or clinically significant ventricular arrhythmias were excluded from the clinical studies. Therefore, the safety of apalutamide in these patients has not been established. If Erleada is prescribed, patients with clinically significant cardiovascular disease should be monitored for risk factors such as hypercholesterolaemia, hypertriglyceridaemia, or other cardio-metabolic disorders (see section&nbsp;4.8). Patients should be treated, if appropriate, after initiating Erleada for these conditions according to established treatment guidelines.</p><p><u>&nbsp;</u></p><p><u>Androgen deprivation therapy may prolong the QT interval</u></p><p>&nbsp;</p><p>In patients with a history of or risk factors for QT prolongation and in patients receiving concomitant medicinal products that might prolong the QT interval (see section&nbsp;4.5), physicians should assess the benefit-risk ratio including the potential for Torsade de pointes prior to initiating Erleada.</p><p>&nbsp;</p><p><u>Severe Cutaneous Adverse Reactions (SCARs)</u></p><p>&nbsp;</p><p>Postmarketing reports of SCARs including drug reaction with eosinophilia and systemic symptoms (DRESS) and Stevens‑Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), which can be life‑threatening or fatal, have been observed in association with Erleada treatment (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Patients should be advised of signs and symptoms suggestive of DRESS or SJS/TEN. If these symptoms are observed, Erleada should be withdrawn immediately and patients should seek immediate medical consultation.</p><p>&nbsp;</p><p>Erleada must not be restarted in patients who have experienced DRESS or SJS/TEN while taking Erleada at any time and an alternative treatment should be considered.</p><p>&nbsp;</p><p><u>Interstitial Lung Disease (ILD)</u></p><p>&nbsp;</p><p>Cases of ILD have been observed in patients treated with apalutamide, including fatal cases. In case of acute onset and/or unexplained worsening of pulmonary symptoms, treatment with apalutamide should be interrupted pending further investigation of these symptoms. If ILD is diagnosed, apalutamide should be discontinued and appropriate treatment initiated as necessary (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 240 mg dose (1 tablet), that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The elimination of apalutamide and formation of its active metabolite, N‑desmethyl apalutamide, is mediated by both CYP2C8 and CYP3A4 to a similar extent at steady-state. No clinically meaningful changes in their overall exposure is expected as a result of drug interaction with inhibitors or inducers of CYP2C8 or CYP3A4. Apalutamide is an inducer of enzymes and transporters and may lead to an increase in elimination of many commonly used medicinal products.</p><p><u>&nbsp;</u></p><p><u>Potential for other medicinal products to affect apalutamide exposures</u></p><p><u>&nbsp;</u></p><p><em>Medicinal products</em><em> that inhibit CYP2C8</em></p><p>&nbsp;</p><p>CYP2C8 plays a role in the elimination of apalutamide and in the formation of its active metabolite. In a drug‑drug interaction study, the C<sub>max</sub> of apalutamide decreased by 21% while AUC increased by 68% following co‑administration of apalutamide 240&nbsp;mg single dose with gemfibrozil (strong CYP2C8 inhibitor). For the active moieties (sum of apalutamide plus the potency adjusted active metabolite), C<sub>max</sub> decreased by 21% while AUC increased by 45%. No initial dose adjustment is necessary when Erleada is co‑administered with a strong inhibitor of CYP2C8 (e.g., gemfibrozil, clopidogrel) however, a reduction of the Erleada dose based on tolerability should be considered (see section&nbsp;4.2). Mild or moderate inhibitors of CYP2C8 are not expected to affect the exposure of apalutamide.</p><p>&nbsp;</p><p><em>Medicinal products that inhibit CYP3A4</em></p><p>&nbsp;</p><p>CYP3A4 plays a role in the elimination of apalutamide and in the formation of its active metabolite. In a drug‑drug interaction study, the C<sub>max</sub> of apalutamide decreased by 22% while AUC was similar following co‑administration of Erleada as a 240&nbsp;mg single dose with itraconazole (strong CYP3A4 inhibitor). For the active moieties (sum of apalutamide plus the potency adjusted active metabolite), C<sub>max</sub> decreased by 22% while AUC was again similar. No initial dose adjustment is necessary when Erleada is co‑administered with a strong inhibitor of CYP3A4 (e.g., ketoconazole, ritonavir, clarithromycin) however, a reduction of the Erleada dose based on tolerability should be considered (see section&nbsp;4.2). Mild or moderate inhibitors of CYP3A4 are not expected to affect the exposure of apalutamide.</p><p>&nbsp;</p><p><em>Medicinal products that induce CYP3A4 or CYP2C8</em></p><p>&nbsp;</p><p>The effects of CYP3A4 or CYP2C8 inducers on the pharmacokinetics of apalutamide have not been evaluated <em>in vivo</em>. Based on the drug-drug interaction study results with strong CYP3A4 inhibitor or strong CYP2C8 inhibitor, CYP3A4 or CYP2C8 inducers are not expected to have clinically relevant effects on the pharmacokinetics of apalutamide and the active moieties therefore no dose adjustment is necessary when Erleada is co-administered with inducers of CYP3A4 or CYP2C8.</p><p><u>&nbsp;</u></p><p><u>Potential for apalutamide to affect exposures to other medicinal products</u></p><p><u>&nbsp;</u></p><p>Apalutamide is a potent enzyme inducer and increases the synthesis of many enzymes and transporters; therefore, interaction with many common medicinal products that are substrates of enzymes or transporters is expected. The reduction in plasma concentrations can be substantial, and lead to lost or reduced clinical effect. There is also a risk of increased formation of active metabolites.</p><p><u>&nbsp;</u></p><p><em>Drug metabolising enzymes</em></p><p>&nbsp;</p><p><em>In vitro</em> studies showed that apalutamide and N‑desmethyl apalutamide are moderate to strong CYP3A4 and CYP2B6 inducers, are moderate inhibitors of CYP2B6 and CYP2C8, and weak inhibitors of CYP2C9, CYP2C19, and CYP3A4. Apalutamide and N‑desmethyl apalutamide do not affect CYP1A2 and CYP2D6 at therapeutically relevant concentrations. The effect of apalutamide on CYP2B6 substrates has not been evaluated <em>in vivo</em> and the net effect is presently unknown. When substrates of CYP2B6 (e.g., efavirenz) are administered with Erleada, monitoring for an adverse reaction and evaluation for loss of efficacy of the substrate should be performed and dose adjustment of the substrate may be required to maintain optimal plasma concentrations.</p><p>&nbsp;</p><p>In humans, apalutamide is a strong inducer of CYP3A4 and CYP2C19, and a weak inducer of CYP2C9. In a drug‑drug interaction study using a cocktail approach, co‑administration of apalutamide with single oral doses of sensitive CYP substrates resulted in a 92% decrease in the AUC of midazolam (CYP3A4 substrate), 85% decrease in the AUC of omeprazole (CYP2C19 substrate), and 46% decrease in the AUC of S‑warfarin (CYP2C9 substrate). Apalutamide did not cause clinically meaningful changes in exposure to the CYP2C8 substrate. Concomitant use of Erleada with medicinal products that are primarily metabolised by CYP3A4 (e.g., darunavir, felodipine, midazolam, simvastatin), CYP2C19 (e.g., diazepam, omeprazole), or CYP2C9 (e.g., warfarin, phenytoin) can result in lower exposure to these medicinal products. Substitution for these medicinal products is recommended when possible or evaluation for loss of efficacy should be performed if the medicinal product is continued. If given with warfarin, INR should be monitored during Erleada treatment.</p><p>&nbsp;</p><p>Induction of CYP3A4 by apalutamide suggests that UDP‑glucuronosyl transferase (UGT) may also be induced via activation of the nuclear pregnane X receptor (PXR). Concomitant administration of Erleada with medicinal products that are substrates of UGT (e.g., levothyroxine, valproic acid) can result in lower exposure to these medicinal products. When substrates of UGT are co‑administered with Erleada, evaluation for loss of efficacy of the substrate should be performed and dose adjustment of the substrate may be required to maintain optimal plasma concentrations.</p><p>&nbsp;</p><p><em>Drug transporters</em></p><p>&nbsp;</p><p>Apalutamide was shown to be a weak inducer of P‑glycoprotein (P‑gp), breast cancer resistance protein (BCRP), and organic anion transporting polypeptide 1B1 (OATP1B1) clinically. A drug‑drug interaction study using a cocktail approach showed that co‑administration of apalutamide with single oral doses of sensitive transporter substrates resulted in a 30% decrease in the AUC of fexofenadine (P‑gp substrate) and 41% decrease in the AUC of rosuvastatin (BCRP/OATP1B1 substrate) but had no impact on C<sub>max</sub>. Concomitant use of Erleada with medicinal products that are substrates of P‑gp (e.g., colchicine, dabigatran etexilate, digoxin), BCRP or OATP1B1 (e.g., lapatinib, methotrexate, rosuvastatin, repaglinide) can result in lower exposure of these medicinal products. When substrates of P‑gp, BCRP or OATP1B1 are co‑administered with Erleada, evaluation for loss of efficacy of the substrate should be performed and dose adjustment of the substrate may be required to maintain optimal plasma concentrations.</p><p>&nbsp;</p><p>Based on <em>in vitro</em> data, inhibition of organic cation transporter&nbsp;2 (OCT2), organic anion transporter&nbsp;3 (OAT3) and multidrug and toxin extrusions (MATEs) by apalutamide and its N‑desmethyl metabolite cannot be excluded. No <em>in vitro</em> inhibition of organic anion transporter 1 (OAT1) was observed.</p><p>&nbsp;</p><p><em>GnRH Analog</em></p><p>&nbsp;</p><p>In mHSPC subjects receiving leuprolide acetate (a GnRH analog), co-administration with apalutamide had no apparent effect on the steady-state exposure of leuprolide.</p><p>&nbsp;</p><p><u>Medicinal products which prolong the QT interval</u></p><p>&nbsp;</p><p>Since androgen deprivation treatment may prolong the QT interval, the concomitant use of Erleada with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes such as class IA (e.g., quinidine, disopyramide) or class III (e.g., amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics (e.g. haloperidol), etc. should be carefully evaluated (see section&nbsp;4.4).</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Contraception in males and females</u></p><p>&nbsp;</p><p>It is not known whether apalutamide or its metabolites are present in semen. Erleada may be harmful to a developing foetus. For patients having sex with female partners of reproductive potential, a condom should be used along with another highly effective contraceptive method during treatment and for 3&nbsp;months after the last dose of Erleada.</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Erleada is contraindicated in women who are or may become pregnant (see section&nbsp;4.3). Based on an animal reproductive study and its mechanism of action, Erleada may cause foetal harm and loss of pregnancy when administered to a pregnant woman. There are no data available from the use of Erleada in pregnant women.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>It is unknown whether apalutamide/metabolites are excreted in human milk. A risk to the suckling child cannot be excluded. Erleada should not be used during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Based on animal studies, Erleada may decrease fertility in males of reproductive potential (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Erleada has no or negligible influence on the ability to drive and use machines. However, seizures have been reported in patients taking Erleada. Patients should be advised of this risk in regards to driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most common adverse reactions are fatigue (26%), skin rash (26% of any grade and 6% Grade 3 or 4), hypertension (22%), hot flush (18%), arthralgia (17%), diarrhoea (16%), fall (13%), and weight decreased (13%). Other important adverse reactions include fractures (11%) and hypothyroidism (8%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions observed during clinical studies and/or in post‑marketing experience are listed below by frequency category. Frequency categories are defined as follows: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1&nbsp;000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10&nbsp;000 to &lt;&nbsp;1/1&nbsp;000); very rare (&lt;&nbsp;1/10&nbsp;000) and not known (frequency cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction and frequency</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p>common: hypothyroidism<sup>a</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>very common: decreased appetite</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>common: hypercholesterolaemia, hypertriglyceridaemia</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>common: dysgeusia, ischaemic cerebrovascular disorders<sup>b</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>uncommon: seizure<sup>c</sup> (see section&nbsp;4.4), restless legs syndrome</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>common: ischaemic heart disease<sup>d</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>not known: QT prolongation (see sections&nbsp;4.4 and 4.5)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>very common: hot flush, hypertension</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>not known: interstitial lung disease<sup>f</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>very common: diarrhoea</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>very common: skin rash<sup>e</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>common: pruritus, alopecia</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>not known: drug reaction with eosinophilia and systemic symptoms (DRESS)<sup>f</sup>, Stevens‑Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)<sup>f</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>very common: fracture<sup>g</sup>, arthralgia</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>common: muscle spasm</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>very common: fatigue</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>very common: weight decreased</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>very common: fall</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp; Includes hypothyroidism, blood thyroid stimulating hormone increased, thyroxine decreased, autoimmune thyroiditis, thyroxine free decreased, tri‑iodothyronine decreased</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; Includes transient ischaemic attack, cerebrovascular accident, cerebrovascular disorder, ischaemic stroke, carotid arteriosclerosis, carotid artery stenosis, hemiparesis, lacunar infarction, lacunar stroke, thrombotic cerebral infarction, vascular encephalopathy, cerebellar infarction, cerebral infarction, and cerebral ischaemia</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp; Includes tongue biting</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp; Includes angina pectoris, angina unstable, myocardial infarction, acute myocardial infarction, coronary artery occlusion, coronary artery stenosis, acute coronary syndrome, arteriosclerosis coronary artery, cardiac stress test abnormal, troponin increased, myocardial ischaemia</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp; See &ldquo;Skin rash&rdquo; under &ldquo;Description of selected adverse reactions&rdquo;</p><p><sup>f</sup>&nbsp;&nbsp;&nbsp; See section&nbsp;4.4</p><p><sup>g</sup>&nbsp;&nbsp;&nbsp; Includes rib fracture, lumbar vertebral fracture, spinal compression fracture, spinal fracture, foot fracture, hip fracture, humerus fracture, thoracic vertebral fracture, upper limb fracture, fractured sacrum, hand fracture, pubis fracture, acetabulum fracture, ankle fracture, compression fracture, costal cartilage fracture, facial bones fracture, lower limb fracture, osteoporotic fracture, wrist fracture, avulsion fracture, fibula fracture, fractured coccyx, pelvic fracture, radius fracture, sternal fracture, stress fracture, traumatic fracture, cervical vertebral fracture, femoral neck fracture, tibia fracture. See below.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Skin rash</em></p><p>&nbsp;</p><p>Skin rash associated with apalutamide was most commonly described as macular or maculo‑papular. Skin rash included rash, rash maculo‑papular, rash generalised, urticaria, rash pruritic, rash macular, conjunctivitis, erythema multiforme, rash papular, skin exfoliation, genital rash, rash erythematous, stomatitis, drug eruption, mouth ulceration, rash pustular, blister, papule, pemphigoid, skin erosion, dermatitis, and rash vesicular. Adverse reactions of skin rash were reported for 26% of patients treated with apalutamide. Grade&nbsp;3 skin rashes (defined as covering &gt;&nbsp;30% body surface area [BSA]) were reported with apalutamide treatment in 6% of patients.</p><p>&nbsp;</p><p>The median days to onset of skin rash was 83&nbsp;days. Seventy-eight percent of patients had resolution of rash with a median of 78 days to resolution. Medicinal products utilised included topical corticosteroids, oral anti-histamines, and 19% of patients received systemic corticosteroids. Among patients with skin rash, dose interruption occurred in 28% and dose reduction occurred in 14% (see section&nbsp;4.2). Skin rash recurred in 59% of patients who had dose interruption. Skin rash led to apalutamide treatment discontinuation in 7% of patients who experienced skin rash.</p><p>&nbsp;</p><p><em>Falls and fractures</em></p><p>&nbsp;</p><p>In Study&nbsp;ARN‑509‑003, fracture was reported for 11.7% of patients treated with apalutamide and 6.5% of patients treated with placebo. Half of the patients experienced a fall within 7&nbsp;days before the fracture event in both treatment groups. Falls were reported for 15.6% of patients treated with apalutamide <em>versus</em> 9.0% of patients treated with placebo (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Ischaemic heart disease and ischaemic cerebrovascular disorders</em></p><p>&nbsp;</p><p>In a randomised study (SPARTAN) of patients with nmCRPC, ischaemic heart disease occurred in 4% of patients treated with apalutamide and 3% of patients treated with placebo. In a randomised study (TITAN) in patients with mHSPC, ischaemic heart disease occurred in 4% of patients treated with apalutamide and 2% of patients treated with placebo. Across the SPARTAN and TITAN studies, 6&nbsp;patients (0.5%) treated with apalutamide and 2&nbsp;patients (0.2%) treated with placebo died from ischaemic heart disease (see section&nbsp;4.4).</p><p>&nbsp;</p><p>In the SPARTAN study, with a median exposure of 32.9&nbsp;months for apalutamide and 11.5&nbsp;months for placebo, ischaemic cerebrovascular disorders occurred in 4% of patients treated with apalutamide and 1% of patients treated with placebo (see above). In the TITAN study, ischaemic cerebrovascular disorders occurred in a similar proportion of patients in the apalutamide (1.5%) and placebo (1.5%) groups. Across the SPARTAN and TITAN studies, 2&nbsp;patients (0.2%) treated with apalutamide and no patients treated with placebo died from an ischaemic cerebrovascular disorder (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Hypothyroidism</em></p><p>&nbsp;</p><p>Hypothyroidism was reported for 8% of patients treated with apalutamide and 2% of patients treated with placebo based on assessments of thyroid‑stimulating hormone (TSH) every 4&nbsp;months. There were no grade&nbsp;3 or 4 adverse events. Hypothyroidism occurred in 30% of patients already receiving thyroid replacement therapy in the apalutamide arm and in 3% of patients in the placebo arm. In patients not receiving thyroid replacement therapy, hypothyroidism occurred in 7% of patients treated with apalutamide and in 2% of patients treated with placebo. Thyroid replacement therapy, when clinically indicated, should be initiated or dose‑adjusted (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effects:</p><p>&nbsp;</p><p><strong>Saudi Arabia:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: npc.drug@sfda.gov.sa</p><p>-&nbsp; &nbsp; &nbsp; &nbsp; Website: https://ade.sfda.gov.sa/</p><p><strong>Other GCC States</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no known specific antidote for apalutamide overdose. In the event of an overdose, Erleada should be stopped and general supportive measures should be undertaken until clinical toxicity has been diminished or resolved. Adverse reactions in the event of an overdose has not yet been observed, it is expected that such reactions would resemble the adverse reactions listed in section&nbsp;4.8.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Endocrine therapy, anti-androgens, ATC code: L02BB05</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Apalutamide is an orally administered, selective Androgen Receptor (AR) inhibitor that binds directly to the ligand‑binding domain of the AR. Apalutamide prevents AR nuclear translocation, inhibits DNA binding, impedes AR‑mediated transcription, and lacks androgen receptor agonist activity. Apalutamide treatment decreases tumour cell proliferation and increases apoptosis leading to potent antitumour activity. A major metabolite, N‑desmethyl apalutamide, exhibited one‑third the <em>in vitro</em> activity of apalutamide.</p><p>&nbsp;</p><p><u>Cardiac electrophysiology</u></p><p>&nbsp;</p><p>The effect of apalutamide 240 mg once daily on the QTc interval was assessed in an open-label, uncontrolled, multi-centre, single-arm dedicated QT study in 45 patients with CRPC. At steady-state, the maximum mean QTcF change from baseline was 12.4 ms (2-sided 90% upper CI: 16.0 ms). An exposure-QT analysis suggested a concentration-dependent increase in QTcF for apalutamide and its active metabolite.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The efficacy and safety of apalutamide has been established in two Phase 3 randomised, placebo-controlled studies, Study ARN-509-003 (nmCRPC) and 56021927PCR3002 (mHSPC).</p><p>&nbsp;</p><p><em>TITAN: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)</em></p><p>&nbsp;</p><p>TITAN was a randomised, double-blind, placebo-controlled, multinational, multicentre clinical study in which 1052 patients with mHSPC were randomised (1:1) to receive either apalutamide orally at a dose of 240&nbsp;mg once daily (N&nbsp;=&nbsp;525) or placebo once daily (N&nbsp;=&nbsp;527). All patients were required to have at least one bone metastasis on Technetium&nbsp;<sup>99m</sup> bone scan. Patients were excluded if the site of metastases was limited to either the lymph nodes or viscera (e.g., liver or lung). All patients in the TITAN study received concomitant GnRH analog or had prior bilateral orchiectomy. Around 11% of patients received prior treatment with docetaxel (maximum of 6 cycles, last dose &le;&nbsp;2 months prior to randomisation and maintained response prior to randomisation). The exclusion criteria included known brain metastases; prior treatment with other next generation anti-androgens (eg, enzalutamide), CYP17 inhibitors (eg, abiraterone acetate), immunotherapy (eg, sipuleucel-T), radiopharmaceutical agents or other treatments for prostate cancer; or history of seizure or condition that may predispose to seizure. Patients were stratified by Gleason score at diagnosis, prior docetaxel use, and region of the world. Patients with both high- and low-volume mHSPC were eligible for the study. High-volume disease was defined as either visceral metastases and at least 1 bone lesion or at least 4 bone lesions, with at least 1 bone lesion outside of the vertebral column or pelvis. Low-volume disease was defined as the presence of bone lesion(s) not meeting the definition of high-volume.</p><p>&nbsp;</p><p>The following patient demographics and baseline disease characteristics were balanced between the treatment arms. The median age was 68&nbsp;years (range 43-94) and 23% of patients were 75&nbsp;years of age or older. The racial distribution was 68% Caucasian, 22% Asian, and 2% Black. Sixty-three percent (63%) of patients had high-volume disease and 37% had low-volume disease. Sixteen percent (16%) of patients had prior surgery, radiotherapy of the prostate or both. A majority of patients had a Gleason score of 7 or higher (92%). Sixty-eight percent (68%) of patients received prior treatment with a first‑generation anti-androgen in the non-metastatic setting. Although criteria for castration resistance were not determined at baseline, 94% of patients demonstrated a decrease in prostate specific antigen (PSA) from initiation of androgen deprivation therapy (ADT) to first dose of apalutamide or placebo. All patients except one in the placebo group, had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 at study entry. Among the patients who discontinued study treatment (N&nbsp;=&nbsp;271 for placebo and N&nbsp;=&nbsp;170 for Erleada), the most common reason for discontinuation in both arms was disease progression. A greater proportion (73%) of patients treated with placebo received subsequent anti-cancer therapy compared to patients treated with Erleada (54%).</p><p>&nbsp;</p><p>The major efficacy outcome measures of the study were overall survival (OS) and radiographic progression-free survival (rPFS). Efficacy results of TITAN are summarised in Table 2 and Figures&nbsp;1 and 2.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:631px"><tbody><tr><td colspan="3"><p><strong>Table&nbsp;2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of efficacy results &ndash; Intent-to-treat mHSPC population (TITAN)</strong></p></td></tr><tr><td><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Erleada</strong></p><p><strong>N=525</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=527</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Primary overall survival<sup>a</sup> </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Deaths (%)</p></td><td style="vertical-align:top"><p>83 (16%)</p></td><td style="vertical-align:top"><p>117 (22%)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)</p></td><td style="vertical-align:top"><p>NE (NE, NE)</p></td><td style="vertical-align:top"><p>NE (NE, NE)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)<sup>b</sup></p></td><td style="vertical-align:top"><p>0.671 (0.507, 0.890)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>c</sup></p></td><td style="vertical-align:top"><p>0.0053</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Updated overall survival<sup>d</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Deaths (%)</p></td><td style="vertical-align:top"><p>170 (32%)</p></td><td style="vertical-align:top"><p>235 (45%)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)</p></td><td style="vertical-align:top"><p>NE (NE, NE)</p></td><td style="vertical-align:top"><p>52 (42, NE)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio (95% CI)<sup>b</sup></p></td><td style="vertical-align:top"><p>0.651 (0.534, 0.793)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>c,e</sup></p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Radiographic progression-free survival </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Disease progression or death (%)</p></td><td style="vertical-align:top"><p>134 (26%)</p></td><td style="vertical-align:top"><p>231 (44%)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)</p></td><td style="vertical-align:top"><p>NE (NE, NE)</p></td><td style="vertical-align:top"><p>22.08 (18.46, 32.92)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)<sup>b</sup></p></td><td style="vertical-align:top"><p>0.484 (0.391, 0.600)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>c</sup></p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp; This is based on the pre-specified interim analysis with a median follow‑up time of 22&nbsp;months.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp; Hazard ratio is from stratified proportional hazards model. Hazard ratio &lt;&nbsp;1 favours active treatment.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp; p-value is from the log-rank test stratified by Gleason score at diagnosis (&le;&nbsp;7 vs. &gt;&nbsp;7), Region (NA/EU vs. Other Countries) and Prior docetaxel use (Yes vs. No).</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp; Median follow‑up time of 44&nbsp;months.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp; This p‑value is nominal instead of being used for formal statistical testing.</p><p>NE=Not Estimable</p></td></tr></tbody></table><p>&nbsp;</p><p>A statistically significant improvement in OS and rPFS was demonstrated in patients randomised to receive Erleada compared with patients randomised to receive placebo in the primary analysis. An updated OS analysis was conducted at the time of final study analysis when 405 deaths were observed with a median follow-up of 44&nbsp;months. Results from this updated analysis were consistent with those from the pre‑specified interim analysis. The improvement in OS was demonstrated even though 39% of patients in the placebo arm crossed over to receive Erleada, with a median treatment of 15&nbsp;months on Erleada crossover.</p><p>&nbsp;</p><p>Consistent improvement in rPFS was observed across patient subgroups including high- or low-volume disease, metastasis stage at diagnosis (M0 or M1), prior docetaxel use (yes or no), age (&lt;&nbsp;65, &ge;&nbsp;65, or &ge;&nbsp;75 years old), baseline PSA above median (yes or no), and number of bone lesions (&le;&nbsp;10 or &gt;&nbsp;10).</p><p>&nbsp;</p><p>Consistent improvement in OS was observed across patient subgroups including high- or low-volume disease, metastasis stage at diagnosis (M0 or M1), and Gleason score at diagnosis (&le;&nbsp;7 vs. &gt;&nbsp;7).</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_2" o:spid="_x0000_i1028" type="#_x0000_t75"
 alt="A graph with numbers and lines&#10;&#10;Description automatically generated"
 style='width:531pt;height:477pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/RAljasmi/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title="A graph with numbers and lines&#10;&#10;Description automatically generated"/>
</v:shape><![endif]--><img width="708" height="636" alt="" vspace="0" hspace="0" border="0" style="width:708px;height:636px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/RAljasmi/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" /></p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_11" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:434.4pt;
 height:375pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/RAljasmi/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="579" height="500" alt="" vspace="0" hspace="0" border="0" style="width:579px;height:500px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/RAljasmi/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png" /></p><p>&nbsp;</p><p>Treatment with Erleada statistically significantly delayed the initiation of cytotoxic chemotherapy (HR&nbsp;=&nbsp;0.391, CI&nbsp;=&nbsp;0.274, 0.558; p&nbsp;&lt;&nbsp;0.0001), resulting in a 61% reduction of risk for subjects in the treatment arm compared to the placebo arm.</p><p>&nbsp;</p><p><em>SPARTAN: Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC)</em></p><p>&nbsp;</p><p>A total of 1207&nbsp;subjects with NM‑CRPC were randomised 2:1 to receive either apalutamide orally at a dose of 240&nbsp;mg once daily in combination with androgen deprivation therapy (ADT) (medical castration or prior surgical castration) or placebo with ADT in a multicentre, double‑blind, clinical study (Study&nbsp;ARN‑509‑003). Subjects enrolled had a Prostate Specific Antigen (PSA) Doubling Time (PSADT) &le;&nbsp;10&nbsp;months, considered to be at high risk of imminent metastatic disease and prostate cancer‑specific death. All subjects who were not surgically castrated received ADT continuously throughout the study. PSA results were blinded and were not used for treatment discontinuation. Subjects randomised to either arm were to continue treatment until disease progression defined by blinded central imaging review (BICR), initiation of new treatment, unacceptable toxicity or withdrawal.</p><p>&nbsp;</p><p>The following patient demographics and baseline disease characteristics were balanced between the treatment arms. The median age was 74&nbsp;years (range&nbsp;48‑97) and 26% of subjects were 80&nbsp;years of age or older. The racial distribution was 66% Caucasian, 5.6% Black, 12% Asian, and 0.2% Other. Seventy‑seven percent (77%) of subjects in both treatment arms had prior surgery or radiotherapy of the prostate. A majority of subjects had a Gleason score of 7 or higher (81%). Fifteen percent (15%) of subjects had &lt;&nbsp;2&nbsp;cm pelvic lymph nodes at study entry. Seventy‑three percent (73%) of subjects received prior treatment with a first generation anti‑androgen; 69% of subjects received bicalutamide and 10% of subjects received flutamide. All subjects enrolled were confirmed to be non‑metastatic by blinded central imaging review and had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) performance status score of 0 or 1 at study entry.</p><p>&nbsp;</p><p>Metastasis‑free survival (MFS) was the primary endpoint, defined as the time from randomisation to the time of first evidence of BICR‑confirmed bone or soft tissue distant metastasis or death due to any cause, whichever occurred first. Treatment with Erleada significantly improved MFS. Erleada decreased the relative risk of distant metastasis or death by 70% compared to placebo (HR&nbsp;=&nbsp;0.30; 95% CI: 0.24, 0.36; p&nbsp;&lt;&nbsp;0.0001). The median MFS for Erleada was 41&nbsp;months and was 16&nbsp;months for placebo (see Figure&nbsp;3). Consistent improvement in MFS with Erleada was observed for all pre‑specified subgroups, including age, race, region of the world, nodal status, prior number of hormonal therapies, baseline PSA, PSA doubling time, baseline ECOG status and use of bone-sparing agents.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_4"
 o:spid="_x0000_i1026" type="#_x0000_t75" style='width:461.4pt;height:323.4pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/RAljasmi/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.png"
  o:title=""/>
</v:shape><![endif]--><img width="615" height="431" alt="" vspace="0" hspace="0" border="0" style="width:615px;height:431px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/RAljasmi/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png" /></p><p>&nbsp;</p><p>Taking account of all data, subjects treated with Erleada and ADT showed significant improvement over those treated with ADT alone for the following secondary endpoints of time to metastasis (HR&nbsp;=&nbsp;0.28; 95% CI: 0.23, 0.34; p&nbsp;&lt;&nbsp;0.0001), progression‑free survival (PFS) (HR&nbsp;=&nbsp;0.30; 95% CI: 0.25, 0.36; p&nbsp;&lt;&nbsp;0.0001); time to symptomatic progression (HR&nbsp;=&nbsp;0.57; 95% CI:&nbsp;0.44, 0.73; p&nbsp;&lt;&nbsp;0.0001); overall survival (OS) (HR&nbsp;=&nbsp;0.78; 95% CI:&nbsp;0.64, 0.96; p&nbsp;=&nbsp;0.0161) and time to initiation of cytotoxic chemotherapy (HR&nbsp;=&nbsp;0.63; 95% CI: 0.49, 0.81; p&nbsp;=&nbsp;0.0002).</p><p>&nbsp;</p><p>Time to symptomatic progression was defined as time from randomisation to development of a skeletal related event, pain/symptoms requiring initiation of a new systemic anti-cancer therapy, or loco-regional tumour progression requiring radiation/surgery. While the overall number of events was small, the difference between the two arms was sufficiently large to reach statistical significance. Treatment with Erleada decreased the risk of symptomatic progression by 43% compared with placebo (HR&nbsp;=&nbsp;0.567; 95% CI: 0.443, 0.725; p&nbsp;&lt;&nbsp;0.0001). The median time to symptomatic progression was not reached in either treatment group.</p><p>&nbsp;</p><p>With median follow-up time of 52.0&nbsp;months, results showed that treatment with Erleada significantly decreased the risk of death by 22% compared with placebo (HR&nbsp;=&nbsp;0.784; 95% CI: 0.643, 0.956; 2‑sided p&nbsp;=&nbsp;0.0161). The median OS was 73.9&nbsp;months for the Erleada arm and 59.9&nbsp;months for the placebo arm. The pre-specified alpha boundary (p&nbsp;&le;&nbsp;0.046) was crossed and statistical significance was achieved. This improvement was demonstrated even though 19% of patients in the placebo arm received Erleada as subsequent therapy.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_5"
 o:spid="_x0000_i1025" type="#_x0000_t75" alt="A close up of a map&#10;&#10;Description automatically generated"
 style='width:423.6pt;height:298.2pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/RAljasmi/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.png"
  o:title="A close up of a map&#10;&#10;Description automatically generated"/>
</v:shape><![endif]--><img width="565" height="398" alt="" vspace="0" hspace="0" border="0" style="width:565px;height:398px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/RAljasmi/AppData/Local/Temp/1/msohtmlclip1/01/clip_image007.png" /></p><p>&nbsp;</p><p>Treatment with Erleada significantly decreased the risk of initiating cytotoxic chemotherapy by 37% compared with placebo (HR&nbsp;=&nbsp;0.629; 95% CI: 0.489, 0.808; p&nbsp;=&nbsp;0.0002) demonstrating statistically significant improvement for Erleada versus placebo. The median time to the initiation of cytotoxic chemotherapy was not reached for either treatment arm.</p><p>&nbsp;</p><p>PFS‑2, defined as the time to death or disease progression by PSA, radiographic, or symptomatic progression on or after first subsequent therapy was longer for subjects treated with Erleada compared to those treated with placebo. Results demonstrated a 44% reduction in risk of PFS-2 with Erleada versus placebo (HR&nbsp;=&nbsp;0.565, 95% CI: 0.471, 0.677; p&nbsp;&lt;&nbsp;0.0001).</p><p>&nbsp;</p><p>There were no detrimental effects to overall health-related quality of life with the addition of Erleada to ADT and a small but not clinically meaningful difference in change from baseline in favour of Erleada observed in the analysis of the Functional Assessment of Cancer Therapy‑Prostate (FACT‑P) total score and subscales.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Erleada in all subsets of the paediatric population in advanced prostate cancer. See section&nbsp;4.2 for information on paediatric use.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following repeat once‑daily dosing, apalutamide exposure (C<sub>max</sub> and area under the concentration curve [AUC]) increased in a dose‑proportional manner across the dose range of 30 to 480&nbsp;mg. Following administration of 240&nbsp;mg once daily, apalutamide steady state was achieved after 4&nbsp;weeks and the mean accumulation ratio was approximately 5‑fold relative to a single dose. At steady‑state, mean (CV%) C<sub>max</sub> and AUC values for apalutamide were 6&nbsp;&micro;g/mL (28%) and 100&nbsp;&micro;g.h/mL (32%), respectively. Daily fluctuations in apalutamide plasma concentrations were low, with mean peak‑to‑trough ratio of 1.63. An increase in apparent clearance (CL/F) was observed with repeat dosing, likely due to induction of apalutamide&rsquo;s own metabolism.</p><p>&nbsp;</p><p>At steady‑state, the mean (CV%) C<sub>max</sub> and AUC values for the major active metabolite, N‑desmethyl apalutamide, were 5.9&nbsp;&micro;g/mL (18%) and 124&nbsp;&micro;g.h/mL (19%), respectively. N‑desmethyl apalutamide is characterised by a flat concentration‑time profile at steady‑state with a mean peak‑to‑trough ratio of 1.27. Mean (CV%) AUC metabolite/parent drug ratio for N‑desmethyl apalutamide following repeat‑dose administration was about 1.3 (21%). Based on systemic exposure, relative potency, and pharmacokinetic properties, N‑desmethyl apalutamide likely contributed to the clinical activity of apalutamide.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>After oral administration, median time to achieve peak plasma concentration (t<sub>max</sub>) was 2&nbsp;hours (range: 1 to 5&nbsp;hours). Mean absolute oral bioavailability is approximately 100%, indicating that apalutamide is completely absorbed after oral administration.</p><p>&nbsp;</p><p>Administration of apalutamide to healthy subjects under fasting conditions and with a high‑fat meal resulted in no clinically relevant changes in C<sub>max</sub> and AUC. Median time to reach t<sub>max</sub> was delayed about 2&nbsp;hours with food (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Apalutamide is not ionisable under relevant physiological pH condition, therefore acid lowering agents (e.g., proton pump inhibitor, H<sub>2</sub>‑receptor antagonist, antacid) are not expected to affect the solubility and bioavailability of apalutamide.</p><p><u>&nbsp;</u></p><p><em>In vitro</em>, apalutamide and its N‑desmethyl metabolite are substrates for P‑gp. Because apalutamide is completely absorbed after oral administration, P‑gp does not limit the absorption of apalutamide and therefore, inhibition or induction of P‑gp is not expected to affect the bioavailability of apalutamide.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>&nbsp;</p><p>The mean apparent volume of distribution at steady‑state of apalutamide is about 276&nbsp;L. The volume of distribution of apalutamide is greater than the volume of total body water, indicative of extensive extravascular distribution.</p><p>&nbsp;</p><p>Apalutamide and N‑desmethyl apalutamide are 96% and 95% bound to plasma proteins, respectively, and mainly bind to serum albumin with no concentration dependency.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Following single oral administration of <sup>14</sup>C‑labelled apalutamide 240&nbsp;mg, apalutamide, the active metabolite, N‑desmethyl apalutamide, and an inactive carboxylic acid metabolite accounted for the majority of the <sup>14</sup>C‑radioactivity in plasma, representing 45%, 44%, and 3%, respectively, of the total <sup>14</sup>C‑AUC.</p><p>&nbsp;</p><p>Metabolism is the main route of elimination of apalutamide. It is metabolised primarily by CYP2C8 and CYP3A4 to form N‑desmethyl apalutamide. Apalutamide and N‑desmethyl apalutamide are further metabolised to form the inactive carboxylic acid metabolite by carboxylesterase. The contribution of CYP2C8 and CYP3A4 in the metabolism of apalutamide is estimated to be 58% and 13% following single dose but the level of contribution is expected to change at steady‑state due to induction of CYP3A4 by apalutamide after repeat dose.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Apalutamide, mainly in the form of metabolites, is eliminated primarily via urine. Following a single oral administration of radiolabelled apalutamide, 89% of the radioactivity was recovered up to 70&nbsp;days post‑dose: 65% was recovered in urine (1.2% of dose as unchanged apalutamide and 2.7% as N‑desmethyl apalutamide) and 24% was recovered in faeces (1.5% of dose as unchanged apalutamide and 2% as N‑desmethyl apalutamide).</p><p>&nbsp;</p><p>The apparent oral clearance (CL/F) of apalutamide is 1.3&nbsp;L/h after single dosing and increases to 2.0&nbsp;L/h at steady‑state after once‑daily dosing. The mean effective half‑life for apalutamide in patients is about 3&nbsp;days at steady‑state.</p><p>&nbsp;</p><p><em>In vitro</em> data indicate that apalutamide and its N‑desmethyl metabolite are not substrates for BCRP, OATP1B1 or OATP1B3.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p>The effects of renal impairment, hepatic impairment, age, race, and other extrinsic factors on the pharmacokinetics of apalutamide are summarised below.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>&nbsp;</p><p>A dedicated renal impairment study for apalutamide has not been conducted. Based on the population pharmacokinetic analysis using data from clinical studies in subjects with castration‑resistant prostate cancer (CRPC) and healthy subjects, no significant difference in systemic apalutamide exposure was observed in subjects with pre‑existing mild to moderate renal impairment (estimated glomerular filtration rate [eGFR] between 30 to 89&nbsp;mL/min/1.73&nbsp;m<sup>2</sup><sub>; </sub>N=585) compared to subjects with baseline normal renal function (eGFR&nbsp;&ge;&nbsp;90&nbsp;mL/min/1.73&nbsp;m<sup>2</sup><sub>; </sub>N=372). The potential effect of severe renal impairment or end stage renal disease (eGFR&nbsp;&le;&nbsp;29&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) have not been established due to insufficient data.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>&nbsp;</p><p>A dedicated hepatic impairment study compared the systemic exposure of apalutamide and N‑ desmethyl apalutamide in subjects with baseline mild hepatic impairment (N=8, Child‑Pugh Class A, mean score = 5.3) or moderate hepatic impairment (N=8, Child‑Pugh Class B, mean score = 7.6) <em>versus</em> healthy controls with normal hepatic function (N=8). Following a single oral 240&nbsp;mg dose of apalutamide, the geometric mean ratio (GMR) for AUC and C<sub>max</sub> for apalutamide in subjects with mild impairment was 95% and 102%, respectively, and the GMR for AUC and C<sub>max</sub> of apalutamide in subjects with moderate impairment was 113% and 104%, respectively, compared to healthy control subjects. Clinical and pharmacokinetic data for apalutamide are not available for patients with severe hepatic impairment (Child‑Pugh Class C).</p><p>&nbsp;</p><p><em>Ethnicity and race</em></p><p>&nbsp;</p><p>Based on population pharmacokinetic analysis, there were no clinically relevant differences in apalutamide pharmacokinetics between White (Caucasian or Hispanic or Latino; N=761), Black (of African heritage or African American; N=71), Asian (non‑Japanese; N=58) and Japanese (N=58).</p><p>&nbsp;</p><p><em>Age</em></p><p>&nbsp;</p><p>Population pharmacokinetic analyses showed that age (range: 18 to 94&nbsp;years) does not have a clinically meaningful influence on the pharmacokinetics of apalutamide.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Apalutamide was negative for genotoxicity in a standard battery of <em>in&nbsp;vitro</em> and <em>in&nbsp;vivo</em> tests.</p><p>Apalutamide was not carcinogenic in a 6-month study in the male transgenic (Tg.rasH2) mouse at doses up to 30&nbsp;mg/kg per day, which is 1.2 and 0.5&nbsp;times for apalutamide and N‑desmethyl apalutamide respectively, the clinical exposure (AUC) at the recommended clinical dose of 240&nbsp;mg/day.</p><p>&nbsp;</p><p>In a 2‑year carcinogenicity study in male Sprague‑Dawley rats, apalutamide was administered by oral gavage at doses of 5, 15 and 50&nbsp;mg/kg/day (0.2, 0.7, and 2.5 times the AUC in patients (human exposure at recommended dose of 240&nbsp;mg), respectively). Neoplastic findings were noted including an increased incidence of testicular Leydig cell adenoma and carcinoma at doses greater than or equal to 5&nbsp;mg/kg/day, mammary adenocarcinoma and fibroadenoma at 15&nbsp;mg/kg/day or 50&nbsp;mg/kg/day, and thyroid follicular cell adenoma at 50&nbsp;mg/kg/day. These findings were considered rat‑specific and therefore of limited relevance to humans.</p><p>&nbsp;</p><p>Male fertility is likely to be impaired by treatment with apalutamide based on findings in repeat‑dose toxicology studies which were consistent with the pharmacological activity of apalutamide. In repeat‑dose toxicity studies in male rats and dogs, atrophy, aspermia/hypospermia, degeneration and/or hyperplasia or hypertrophy in the reproductive system were observed at doses corresponding to exposures approximately equal to the human exposure based on AUC.</p><p>&nbsp;</p><p>In a fertility study in male rats, a decrease in sperm concentration and motility, copulation and fertility rates (upon pairing with untreated females) along with reduced weights of the secondary sex glands and epididymis were observed following 4&nbsp;weeks of dosing at doses corresponding to exposures approximately equal to the human exposure based on AUC. Effects on male rats were reversible after 8&nbsp;weeks from the last apalutamide administration.</p><p>&nbsp;</p><p>In a preliminary embryofetal developmental toxicity study in rats, apalutamide caused developmental toxicity when administered at oral doses of 25, 50 or 100&nbsp;mg/kg/day throughout the period of organogenesis (gestational days 6-20). These doses resulted in systemic exposures approximately 2, 4 and 6&nbsp;times, respectively, on an AUC basis, the exposure in humans at the dose of 240&nbsp;mg/day. Findings included non‑pregnant females at 100&nbsp;mg/kg/day and embryofetal lethality (resorptions) at doses &ge;&nbsp;50&nbsp;mg/kg/day, decreased fetal anogenital distance and a misshapen pituitary gland (more rounded shape) at &ge;&nbsp;25&nbsp;mg/kg/day. Skeletal variations (unossified phalanges, supernumerary short thoracolumbar rib(s) and/or abnormalities of the hyoid) were also noted at doses &ge;&nbsp;25&nbsp;mg/kg/day, without resulting in an effect on mean fetal weight.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>&nbsp;</p><p>Colloidal anhydrous silica</p><p>Croscarmellose sodium</p><p>Hypromellose acetate succinate</p><p>Magnesium stearate</p><p>Microcrystalline cellulose (silicified)</p><p>&nbsp;</p><p><u>Film‑coating</u></p><p>&nbsp;</p><p>Glycerol monocaprylocaprate</p><p>Iron oxide black (E172)</p><p>Poly (vinyl alcohol)</p><p>Talc</p><p>Titanium dioxide (E171)</p><p>Macrogol poly (vinyl alcohol) grafted copolymer</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p><p>Store in the original package in order to protect from moisture.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>White high‑density polyethylene (HDPE) bottle with a polypropylene (PP) child‑resistant closure. Each bottle contains 30&nbsp;film‑coated tablets and a total of 2&nbsp;g of silica gel desiccant.</p><p>&nbsp;</p><p>Transparent PVC‑PCTFE film blister with an aluminium push‑through foil sealed inside a child‑resistant wallet pack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 28‑day carton contains 28&nbsp;film coated tablets in 2 cardboard wallet packs of 14&nbsp;film‑coated tablets each.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 30‑day carton contains 30&nbsp;film coated tablets in 3 cardboard wallet packs of 10&nbsp;film‑coated tablets each.</p><p>&nbsp;</p><p>Not all pack types and sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janssen Cilag International NV
Turnhoutseweg 30
B 2340 Beerse
Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7 Decemeber 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>